Sales value of major prescription drugs Japan FY 2022
In fiscal year 2022, Opdivo was the leading medicament in Japan, reaching a sales value of approximately 159 billion Japanese yen. Opdivo is an immunotherapy agent and is mainly used to treat malignant melanoma in Japan.